Stocks and Investing Stocks and Investing
Wed, August 24, 2022
Tue, August 23, 2022

Asthika Goonewardene Maintained (STRO) at Strong Buy with Decreased Target to $21 on, Aug 23rd, 2022


Published on 2024-10-27 22:48:02 - WOPRAI, Asthika Goonewardene
  Print publication without navigation


Asthika Goonewardene of Truist Securities, Maintained "Sutro Biopharma, Inc." (STRO) at Strong Buy with Decreased Target from $37 to $21 on, Aug 23rd, 2022.

Asthika has made no other calls on STRO in the last 4 months.



There are 2 other peers that have a rating on STRO. Out of the 2 peers that are also analyzing STRO, 0 agree with Asthika's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Asthika


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $14 on, Monday, May 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $30 on, Wednesday, May 11th, 2022
Contributing Sources